Lenire Tinnitus Management
FDA Approved. Independently Verified. Real World Validated.
Clinical & Real World Evidence show after using Lenire treatment device 91.5% saw clinically significant improvement in tinnitus by week 12 and 89.2% reported Lenire was beneficial
Lenire® Tinnitus Treatment at Audiology Planet
Manage your tinnitus with the groundbreaking Lenire® Therapy. The first-of-its-kind CE marked, FDA approved bimodal neuromodulation device that empowers you to manage tinnitus from the comfort of home.
Lenire (Len-ear), which is Latin for ‘soothe’, is the only commercially available, clinically trialed, dual mode tinnitus treatment device approved by the US FDA.
Safety and effectiveness trialed with 600+ patients.
Successfully trialed with real-world patients.
Technology with over 136 worldwide patents.
More effective than sound for moderate or worse tinnitus.
Sound Therapy
What Is Lenire & How It Works
Lenire® is a prescription-only, non-invasive medical device that retrains the brain’s perception of tinnitus by combining:
- Sound therapy via Bluetooth headphones
- Gentle electrical pulses delivered to the tongue through a mouthpiece
This dual stimulation — known as bimodal neuromodulation — fosters lasting neural changes that reduce tinnitus loudness and perception* (see the research references on this page).
Who Can Benefit
Lenire is suitable for adults experiencing:
- Persistent bilateral ringing, buzzing, or hissing for 3+ months
- Tinnitus severity in moderate to severe range on a popular tinnitus questionnaire
- No reliance on medication—Lenire offers a drug free, safe, at home solution
Each patient starts with a full hearing and tinnitus assessment before being tailored an individualised treatment plan at Audiology Planet.
Tinnitus Treatment Device
Effective, Safe and Calming
Convenient and Calming
Lenire is a compact device that can be used in any quiet space, making it easy easy to fit relaxing Lenire sessions into your lifestyle.
Outperforms Sound-Alone
Lenire’s dual mode approach is proven in a clinical trial to outperform sound-only therapy for moderate or worse tinnitus.
Better Quality of Life
Tinnitus can cause sleep, social, mobility and focus issues. Lenire can set tinnitus to ‘do not disturb’ so you can live life your way.
Typical Treatment Protocol
Typical Treatment Protocol
- Initial consultation & fitting at our Tunbridge Wells or Sevenoaks clinic
- Daily sessions: 2 × 30 minutes (up to 60 minutes total)
- Regular check-ins (in-person / telehealth) every 4–6 weeks
- Most patients complete a 12-week program, with long-term improvements lasting up to a year or more (en.wikipedia.org, nature.com, lenire.com).
Safety & Certification
- CE marked in Europe under MDR
- FDA De Novo approval in 2023 — first-of-its-kind device in US (nature.com)
- Large scale studies and real world usage report no serious device-related issues
Why Choose Audiology Planet?
- Expert Audiology Team: Highly trained in tinnitus and Lenire therapy
- Customised Care: Built around your hearing profile and tinnitus triggers
- Flexible Appointments: In-clinic & telehealth support
- Local Access: Convenient Tunbridge Wells & Sevenoaks locations
Ready to Begin?
Take control of your tinnitus with the most clinically validated device available:
Investment- time and fee
Lenire requires an investment of both your time and money. There is a certain commitment needed from you if you would like to help your tinnitus. If you are living with a bothersome tinnitus, it should be well worth to consider this very important investment.
You’ll use Lenire at home for 30–60 minutes per day, typically over a 12-week period. Therefore, you must find that time within the 24 hours of your day. Treatment device
Treatment fee
The total cost for the Lenire treatment package, including the device, is £3,445, broken down as follows:
Initial assessment and consultation: £195 (non-refundable)
Lenire device and treatment plan (if proceeding): £3,250
If you would like to book your appointment, please let us know a convenient time. You're also welcome to reach out with any questions—we’re here to support you in making the best decision for your tinnitus care.
FAQ :
Lenire is intended for adults aged 18 and over with subjective chronic tinnitus lasting 3+ months. It’s also suitable for patients with hyperacusis
Lenire is generally safe, but it should not be used by people who:
- Have an active implantable device (e.g., pacemaker, defibrillator)
- Are pregnant or have epilepsy
- Have tongue sensitivity issues or oral lesions
- Suffer from neuralgia in the head/neck region
- Have objective-source tinnitus, Meniere’s disease, or oral piercings
Using bimodal neuromodulation, Lenire delivers sound via Bluetooth headphones while applying mild electrical pulses to the tongue.
This dual stimulation retrains the brain to become less reactive to tinnitus
You’ll use Lenire at home for 30–60 minutes per day, typically over a 12-week period. Following completion, a professional review is recommended to assess progress and adjust further treatment if needed
Many patients report meaningful improvement within 6–12 weeks. After completing the 12-week course, your clinician will evaluate your progress and help you decide on next steps
No. Lenire is prescription-based and fitted to individual hearing and stimulation profiles. Sharing could reduce effectiveness or cause discomfort
Clean it after each session using water or 70% isopropyl alcohol wipes, following the rules in the User Manual
You can adjust volume using the device buttons. If you experience sensitivity or discomfort, inform your clinician—they’ll help fine-tune settings
Research Summary
Lenire has been evaluated in multiple clinical trials and real-world clinic networks. In controlled studies, 95% of treatment-compliant participants improved on Tinnitus Handicap Inventory (THI) scores after 12 weeks, and 84% improved on the Tinnitus Functional Index (TFI).³⁴ Large trials (TENT-A1, TENT-A2) showed clinically meaningful reductions in tinnitus distress, with some participants maintaining benefits at follow-up.⁴
The pivotal TENT-A3 study compared 6 weeks of sound-only therapy with 6 weeks of bimodal stimulation in the same individuals. For those with moderate or worse tinnitus, bimodal treatment delivered higher responder rates than sound-only, with no device-related serious adverse events.⁶⁷ Real-world data from UK, European, and US clinics show similar improvements.¹²⁵
Around one-third of participants experienced a temporary increase in tinnitus during treatment; this typically resolved by the end of the study. Not everyone benefits, and durability beyond 12 months is still being explored. This information should not replace medical advice; always consult a clinician before starting treatment.
References
- Neuromod Devices Ltd. The Science of Lenire. www.lenire.com/the-scienceof-lenire
Conlon B, Langguth B, Hamilton C, et al. Science Translational Medicine (2020) 12:564. DOI: 10.1126/scitranslmed.abb2830
Conlon B, Hamilton C, Meade E, et al. Nature Scientific Reports (2022) 12, 10845. https://doi.org/10.1038/s41598-022-13875-x
Boedts M, Buechner A, et al. Nature Communications (2024) 15, 6806. https://www.nature.com/articles/s41467-024-50473-z
McMahan E, Lim H. Communications Medicine (2025) 5, 112. https://www.nature.com/articles/s43856-025-00837-3
Additional clinical and real-world data reported by Neuromod Devices and partner clinics